Status:
COMPLETED
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
Lead Sponsor:
Thomas Lund
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Multiple myeloma (MM) is the second most common hematological disease in Denmark with an incidence of approximately 350 diagnosed cases per year. There is no curative treatment yet, but usually the di...
Detailed Description
This study is a prospective, non-randomized, clinical parallel mixed-methods intervention project using qualitative and quantitative data in the form of semi-structured telephone interviews, focus gro...
Eligibility Criteria
Inclusion
- have relapse of MM.
- be in or have planned to start treatment with Daratumumab SC.
- be cognitively capable to assess any side effects of Daratumumab SC based on the instructions provided.
- be able and willing to register in a timetable and to participate in two semi-structured telephone interviews.
- be able to understand and speak Danish.
- be in possession of a mobile phone (for SMS tracking).
Exclusion
- \- receive other anti-myeloma treatment that require hospitalization with the exception of visit 1 in all cycles with Daratumumab SC administration.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05306587
Start Date
April 1 2022
End Date
January 1 2024
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospital
Odense, Denmark, 5000